Demegen develops novel and natural peptides for the treatment of bacterial and fungal infections. Demegen operates primarily with strategic partners and development efforts are underway for a number of dermatological, ophthalmic, cosmetic and agricultural applications. Other products to be developed include a treatment for cystic fibrosis infections.
| Website | http://www.demegen.com |
| Revenue | $16.9 million |
| Employees | View employees |
| Founded | 1992 |
| Address | 1051 Brinton Rd, Pittsburgh, Pennsylvania 15221, US |
| Phone | +1 412-621-9625 |
| Industry | Business Services General, Pharmaceutical, Biotechnology, Business Services, Health Care, Other Pharmaceuticals and Biotechnology |
| Competitors | Novartis, Amgen, Regeneron, Gilead Sciences, Vertex Pharmaceuticals, Biogen, Incyte, Zymeworks Inc., Lilly India, Sarepta Therapeutics, Inc. +46 more (view full list) |
| SIC | SIC Code 873 Companies, SIC Code 87 Companies |
| NAICS | NAICS Code 541 Companies, NAICS Code 54 Companies, NAICS Code 5417 Companies, NAICS Code 54171 Companies, NAICS Code 541714 Companies |
Looking for a particular Demegen employee's phone or email?
Demegen Questions
The Demegen annual revenue was $16.9 million in 2026.
Demegen is based in Pittsburgh, Pennsylvania.
The NAICS codes for Demegen are [541, 54, 5417, 54171, 541714].
The SIC codes for Demegen are [873, 87].
